Episode Summary
Are your 340B operations fully optimized, or are you secretly missing massive savings? In this episode of 340B Pulse, hosts Mohamed Atif and Salman Asif sit down with healthcare expert Lisa Nezneski to expose the "Orphan Drug Blind Spot."
Many rural and community hospitals mistakenly assume orphan drugs are strictly excluded from their programs. Tune in to discover:
- The $200K–$450K Opportunity: How discretionary manufacturer pricing unlocks massive hidden revenue.
- TPA Bottlenecks: Why overlooked accumulation errors happen and how to quickly fix them.
- Actionable Execution: A practical guide to tracking missing margins and securing leadership buy-in to fund vital community health initiatives.
Resources & Mentions
- 340B Orphan Drug Solutions Estimator Tool - https://340borphandrugsolutions.com
Show Notes
- The true definition of the "Orphan Drug Blind Spot" currently affecting CAHs, SCHs, and RRCs.
- Why most 340B operators falsely assume their programs are already fully maximized.
- he critical difference between strict 340B compliance and navigating discretionary orphan drug pricing.
- How to perform a safe, "first-pass" validation to quickly identify missed accumulation savings.
- Exploring the 340B Orphan Drug Savings estimator tool as an auditing foundation.
- Overcoming the technical bottlenecks caused by Third-Party Administrators (TPAs) completely blocking orphan drug claims.
- The psychological barrier: Addressing why pharmacy teams often fear reporting massive newly-found savings to hospital leadership.
- Strategies for maintaining strict defensibility and documentation to protect these savings during an audit.
- Discretionary Pricing is the Key: While orphan drugs are technically excluded from statutory 340B pricing for certain covered entities, manufacturers often provide discretionary discounts that hospitals fail to claim.
- Massive Budget Impact: Orphan drugs routinely account for 50% to 75% of total drug spend in a $12M–$30M budget.
- TPA Extremes:TPA setups are often either "wide-open" (leading to compliance confusion) or entirely "blocked" (leaving massive savings on the table). Proper NDC routing is essential.
- The $200K–$450K Benchmark: The typical range of new annual revenue Lisa Nezneski discovers in the very first quarter of auditing rural covered entities.
- Reframing the "Miss":Moving pharmacy leaders from a mindset of fear (worrying they'll be blamed for missing past savings) to a mindset of heroism.
- The 340B Orphan Drug Savings Estimator:A discussion on practical tools that allow entities to gauge their missed opportunities quickly without disrupting operations.
- Turning Compliance into Community Value:How capturing these overlooked margins directly translates into funding vital community initiatives (like rural health programs), shifting the pharmacy team from a cost center into an organizational revenue driver.
- Do Not Assume Optimization:Just because your 340B program is running doesn’t mean your orphan drug accumulations are correctly configured.
- Take Tailored Action:Capture savings by actively managing IT communication queues with TPAs and aligning NDCs with actual manufacturer pricing behavior.
- Defensibility Matters:Build robust operational documentation so that when audits occur, the captured savings are transparent and defensible.
- Start Validating Now:Run a first-pass analysis immediately to measure the genuine size of your opportunity before making organizational changes.